Icsi Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Intracytoplasmic sperm injection (ICSI) is an advanced assisted reproductive technique in which a single spermatozoon is injected directly into the cytoplasm of a mature oocyte using a fine glass microneedle (injection pipette) under high-powered inverted microscope magnification. Introduced in 1992 by Palermo et al. at the Vrije Universiteit Brussel, ICSI revolutionised the treatment of severe male factor infertility by enabling fertilisation with even a single viable sperm — bypassing the requirement for sperm-zona pellucida penetration that is impaired in most male factor conditions.

ICSI is now performed in approximately 70% of all IVF cycles globally, including many cycles where conventional insemination would suffice, reflecting its widespread adoption beyond severe male factor indications. The ICSI process begins identically to standard IVF: controlled ovarian stimulation, egg retrieval under sedation, and laboratory culture. On the day of egg retrieval, mature (MII) oocytes are denuded of their cumulus cells and placed under an inverted microscope. A selected spermatozoon is immobilised and aspirated into the injection needle; the needle penetrates the zona pellucida and oolemma, and the sperm is deposited into the oocyte cytoplasm. Fertilisation confirmation (two pronuclei formation) is assessed 16–18 hours later.

ICSI is the primary treatment for severe male factor infertility encompassing oligospermia (sperm count below 5 million/mL), asthenospermia (less than 32% progressive motility), teratospermia (less than 4% normal morphology by Kruger strict criteria), and combined oligo-astheno-teratospermia (OAT). Azoospermia — complete absence of sperm in ejaculate — is treated with surgical sperm retrieval (TESA, PESA, TESE, microTESE) followed by ICSI with retrieved testicular or epididymal sperm.

ICCI is indicated for prior fertilisation failure with conventional IVF insemination (less than 25% fertilisation rate). It is used with surgically retrieved sperm from reconstructive procedures (post-vasectomy reversal failure, obstructive azoospermia from infection or ejaculatory duct obstruction). Couples using preimplantation genetic testing (PGT-A/PGT-M) require ICSI to prevent contamination of embryo biopsies from residual sperm attached to the zona. Frozen or poor-quality sperm samples with limited quantity also warrant ICSI. Some centres use ICSI routinely for advanced maternal age cycles or poor responders, though evidence for benefit beyond male factor indications is limited.

Any couple undergoing IVF with a confirmed male factor diagnosis — semen analysis demonstrating abnormal parameters, positive anti-sperm antibodies, or obstructive/non-obstructive azoospermia — is a candidate for ICSI. Men with retrograde ejaculation can have sperm retrieved from post-ejaculation alkalinised urine for ICSI. Spinal cord injury and ejaculatory failure (neurological or psychogenic) are managed with electroejaculation or penile vibratory stimulation, with resulting sperm processed for ICSI.

Contraindications to ICSI are primarily related to the absence of viable sperm — non-obstructive azoospermia with no sperm found on microTESE has no further fertility option without donor sperm. Genetic assessment is essential before ICSI for male factor: Y-chromosome microdeletion analysis (AZF regions a, b, c) and karyotype should be performed, as AZFa/b deletions predict microTESE failure, and AZFc deletions may be transmitted to male offspring. CFTR mutation testing is required for men with congenital bilateral absence of the vas deferens (CBAVD). Women must have adequate ovarian reserve and be medically fit for stimulation and egg retrieval.

Standard ICSI uses ejaculated spermatozoa processed by density gradient centrifugation and swim-up to select the most motile, morphologically normal sperm. Physiological ICSI (PICSI) uses a hyaluronan-binding dish to select sperm based on their ability to bind hyaluronic acid — a marker of nuclear maturity and lower DNA fragmentation. IMSI (intracytoplasmic morphologically selected sperm injection) uses ultra-high magnification (6,300×) to select sperm with minimal nuclear vacuolation before injection; benefits are debated in randomised trials but may benefit couples with recurrent ICSI failure or high sperm DNA fragmentation.

For non-obstructive azoospermia, microdissection TESE (microTESE) retrieves sperm from the testes under operating microscope magnification, identifying tubules with active spermatogenesis — achieving 50–60% sperm retrieval rates in carefully selected cases. TESA (testicular sperm aspiration) and PESA (percutaneous epididymal sperm aspiration) are simpler office-based procedures for obstructive azoospermia with near-100% retrieval rates.

Sperm DNA fragmentation testing (TUNEL, SCSA assay) evaluates sperm chromatin integrity — high fragmentation (above 25%) is associated with poor embryo development and recurrent pregnancy loss. Antioxidant supplementation (vitamins C/E, CoQ10, folic acid) for 3 months prior to ICSI may reduce DNA fragmentation in some men. Donor sperm ICSI is available when no viable sperm can be retrieved. Shared decision-making between patient and specialist, guided by current evidence-based clinical guidelines and the patient's individual anatomy, comorbidities, and treatment goals, is essential for selecting the most appropriate treatment modality. Pre-treatment specialist consultation, review of relevant investigations, and multidisciplinary input for complex presentations ensure the best possible outcomes.

ICSI achieves fertilisation rates of 70–80% of injected mature oocytes in standard male factor cases, translating to blastocyst formation rates of 45–60% and live birth rates per transfer of 35–50% for women under 38 using own eggs. For obstructive azoospermia with PESA/TESA-retrieved sperm, outcomes are comparable to ejaculated sperm ICSI. For non-obstructive azoospermia with microTESE sperm, fertilisation rates are slightly lower (55–70%) but still clinically acceptable.

ICCI enables biological parenthood for men who would otherwise have no fertility treatment option. Combined with PGT-A, ICSI cycles can select chromosomally normal blastocysts, reducing miscarriage rates substantially. For couples with prior fertilisation failure using conventional IVF, switching to ICSI achieves successful fertilisation in the majority. Cumulative live birth rates from multiple frozen embryo transfers from a single ICSI stimulation cycle now exceed 70% for good-prognosis couples at experienced centres.

ICSI-specific risks include oocyte damage during injection — approximately 3–5% of oocytes are damaged or degenerate after ICSI injection, particularly in inexperienced hands or with fragile oocytes. Oocyte activation failure (failed fertilisation despite technically successful ICSI) occurs in approximately 3% of cycles and may be related to sperm-borne activation factors; calcium ionophore artificial oocyte activation (AOA) is an experimental rescue approach for this rare occurrence.

Genetic concerns are the most important ICSI-specific long-term consideration: ICSI bypasses the natural selection against sperm with genetic abnormalities, potentially transmitting paternal genetic conditions to offspring. Children conceived with ICSI using azoospermic fathers carry modestly elevated rates of sex chromosome abnormalities (1.0% vs 0.2% baseline). AZFc Y-chromosome microdeletions are transmitted to all male offspring, who will also have azoospermia. Imprinting disorders (Beckwith-Wiedemann, Angelman syndromes) have marginally elevated rates in IVF/ICSI children versus spontaneous conception. Standard IVF/stimulation risks (OHSS, multiple pregnancy, egg retrieval complications) apply equally.

Following surgical sperm retrieval procedures (TESA, PESA, microTESE), men recover with scrotal support and analgesia for 3–7 days — microTESE requires longer recovery (1–2 weeks) due to the more extensive testicular exploration. Ice packs and anti-inflammatory analgesia manage scrotal swelling. Sexual activity resumes after 1 week for TESA/PESA and 2–3 weeks for microTESE.

For the female partner, the standard IVF monitoring and recovery protocol applies — egg retrieval recovery takes 24–48 hours, with embryo transfer performed 3–6 days later. Fertilisation check, embryo development assessment, and embryo grading updates are communicated daily by the embryology team. Beta-hCG pregnancy testing is performed 12–14 days after embryo transfer. Male factor couples are offered genetic counselling before ICSI to discuss inheritance risks, options for PGT-M if a specific genetic condition is identified, and the implications of Y-chromosome analysis results.

ICSI adds approximately USD 1,000–2,500 to the base IVF cycle cost in the United States, where complete ICSI-IVF packages total USD 13,000–22,000 including medications. In the UK, ICSI cycles cost GBP 4,000–8,000 excluding medications. MicroTESE for non-obstructive azoospermia costs USD 5,000–10,000 additionally in the US, versus INR 60,000–120,000 (USD 700–1,500) in India.

Medical tourism for ICSI-IVF is highly cost-effective: India offers complete ICSI packages including sperm retrieval procedures and medications for USD 2,500–5,000; Thailand USD 4,000–7,000; Spain and Czech Republic EUR 4,000–7,000. Centres in Mumbai, Chennai, Prague, and Bangkok have ESHRE-accredited embryology laboratories with internationally trained specialists. For azoospermia requiring microTESE plus ICSI, the cost difference between the US and India reaches USD 15,000–25,000, making medical tourism highly economically attractive for appropriate candidates.

When ejaculated sperm quality is poor but not severely abnormal, intrauterine insemination (IUI) with prepared sperm is a lower-intervention alternative — appropriate for mild male factor with greater than 5 million motile sperm post-wash, with 3–6 cycles recommended before escalating to IVF-ICSI. Medical treatment of male infertility — clomiphene citrate, FSH therapy for hypogonadotropic hypogonadism, antioxidant supplementation — may improve semen parameters enough to achieve IUI or conventional IVF success.

Varicocele repair (microsurgical varicocelectomy) significantly improves semen parameters in men with clinical varicocele and abnormal semen analysis — a 2021 meta-analysis showed 70% improvement in total motile sperm count after microsurgical repair, allowing some men to avoid ICSI. For non-obstructive azoospermia where microTESE retrieves no sperm, donor sperm IUI or ICSI is the alternative pathway to parenthood. Adoption and child-free living are non-medical alternatives that should be acknowledged in counselling.